Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis

被引：11

作者：

Athanazio, Rodrigo ^{[1
]}

Cordeiro da Costa, Joao ^{[2
]}

de la Rosa Carrillo, David ^{[3
]}

Angel Martinez-Garcia, Miguel ^{[4
]}

机构：

[1] Univ Sao Paulo, Pulm Div, Heart Inst InCor, Hosp Clin,Fac Med, Sao Paulo, Brazil

[2] Ctr Hosp Leiria, Dept Pneumol, Leiria, Portugal

[3] Platon Hosp, Pneumol Unit, Barcelona, Spain

[4] Polytech & Univ La Fe Hosp, Dept Pneumol, Avda Fernando Abril Marorell S-N, Valencia 46016, Spain

来源：

EXPERT REVIEW OF RESPIRATORY MEDICINE | 2018年 / 12卷 / 07期

关键词：

Bronchiectasis; bronchial infection; inhaled antibiotics; bronchodilators; inhaled steroids; mucus clearance techniques; mucoactive agents; macrolides; mucolytics; hypertonic agents; TERM MACROLIDE TREATMENT; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC BRONCHIAL INFECTION; RECOMBINANT HUMAN DNASE; DRY POWDER MANNITOL; PSEUDOMONAS-AERUGINOSA; LONG-TERM; DOUBLE-BLIND; LUNG-FUNCTION;

D O I：

10.1080/17476348.2018.1481392

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Introduction: In recent years, there has been an increasing number of clinical trials investigating the effect of pharmacological treatments on patients with bronchiectasis.Areas covered: This review provides an overview of current drugs used in bronchiectasis patients as well as those that could make a future contribution to the management of this disease.Expert commentary: Bronchiectasis is a very heterogeneous disease, so it can be studied from a phenotypic standpoint and its pathophysiological mechanisms (endotypes) can be defined. This provides an interesting field of research as it enables the identification of patients suitable for inclusion in specific clinical trials on new drugs.

引用

页码：569 / 584

页数：16

共 133 条

[21] Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis
Bilton, Diana
Henig, Noreen
Morrissey, Brian
Gotfried, Mark
[J]. CHEST, 2006, 130 (05) : 1503 - 1510
[22] Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial
Bilton, Diana
Tino, Gregory
Barker, Alan F.
Chambers, Daniel C.
De Soyza, Anthony
Dupont, Lieven J. A.
O'Dochartaigh, Conor
van Haren, Eric H. J.
Vidal, Luis Otero
Welte, Tobias
Fox, Howard G.
Wu, Jian
Charlton, Brett
[J]. THORAX, 2014, 69 (12) : 1073 - 1079
[23] Phase 3 Randomized Study of the Efficacy and Safety of Inhaled Dry Powder Mannitol for the Symptomatic Treatment of Non-Cystic Fibrosis Bronchiectasis
Bilton, Diana
Daviskas, Evangelia
Anderson, Sandra D.
Kolbe, John
King, Gregory
Stirling, Rob G.
Thompson, Bruce R.
Milne, David
Charlton, Brett
[J]. CHEST, 2013, 144 (01) : 215 - 225
[24] Blackwell TS, 1996, J IMMUNOL, V157, P1630
[25] Blanchette Christopher M, 2017, Med Sci (Basel), V5, DOI 10.3390/medsci5040020
[26] The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections
Blasi, Francesco
Page, Clive
Rossolini, Gian Maria
Pallecchi, Lucia
Matera, Maria Gabriella
Rogliani, Paola
Cazzola, Mario
[J]. RESPIRATORY MEDICINE, 2016, 117 : 190 - 197
[27] Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
Bonfiglio, G
[J]. CHEMOTHERAPY, 2001, 47 (04) : 239 - 242
[28] Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis
Boyton, R. J.
Reynolds, C. J.
Quigley, K. J.
Altmann, D. M.
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 171 (02) : 117 - 123
[29] Braga PC, 1999, ARZNEIMITTEL-FORSCH, V49, P344
[30] The risk of mycobacterial infections associated with inhaled corticosteroid use
Brode, Sarah K.
Campitelli, Michael A.
Kwong, Jeffrey C.
Lu, Hong
Marchand-Austin, Alex
Gershon, Andrea S.
Jamieson, Frances B.
Marras, Theodore K.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (03)

← 1 2 3 4 5 6 7 8 9 10 →